ReviewTropical medicine and infectious disease2018
Onchodermatitis: Where Are We Now?
Review in Tropical medicine and infectious disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Onchocerciasis overview: pathogenesis, clinical spectrum, and therapeutic challenges of a neglected tropical disease.Frontiers in parasitology · 2026Review
- Community's knowledge, perceptions and preventive practices on Onchocerciasis in Jimma zone, Ethiopia, formative mixed study.PLoS neglected tropical diseases · 2024Article
- Factors influencing community acceptability of mass drug administration for the elimination of onchocerciasis in the Asante Akim South Municipal, Ghana.PLoS neglected tropical diseases · 2023Article
- Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside.PLoS neglected tropical diseases · 2022Article
- Ecological assessment of Black Fly (Simuliumdamnosum, Sensulato) breeding sites in two tributaries of Ogun river, Ogun state, Nigeria.Environmental monitoring and assessment · 2022Article
- Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon.BMJ global health · 2021Article
- Zoonotic and vector-borne parasites and epilepsy in low-income and middle-income countries.Nature reviews. Neurology · 2020Review
- Onchocerciasis Elimination: Progress and Challenges.Research and reports in tropical medicine · 2020Review
- Article
- Community Participation in and Perception of Community-Directed Treatment with Ivermectin in Kinshasa, DRC.Tropical medicine and infectious disease · 2019Article
- From river blindness to river epilepsy: Implications for onchocerciasis elimination programmes.PLoS neglected tropical diseases · 2019Article
- Review of the National Program for Onchocerciasis Control in the Democratic Republic of the Congo.Tropical medicine and infectious disease · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Onchocerciasis causes debilitating pruritus and rashes as well as visual impairment and blindness. Prior to control measures, eye disease was particularly prominent in savanna areas of sub-Saharan Africa whilst skin disease was more common across rainforest regions of tropical Africa. Mass drug distribution with ivermectin is changing the global scene of onchocerciasis. There has been successful progressive elimination in Central and Southern American countries and the World Health Organization has set a target for elimination in Africa of 2025. This literature review was conducted to examine progress regarding onchocercal skin disease. PubMed searches were performed using keywords 'onchocerciasis', 'onchodermatitis' and 'onchocercal skin disease' over the past eight years. Articles in English, or with an English abstract, were assessed for relevance, including any pertinent references within the articles. Recent progress in awareness of, understanding and treatment of onchocercal skin disease is reviewed with particular emphasis on publications within the past five years. The global burden of onchodermatitis is progressively reducing and is no longer seen in children in many formerly endemic foci.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.